Summary for 7PUS
| Entry DOI | 10.2210/pdb7pus/pdb |
| Related | 5O7I |
| Descriptor | Mitogen-activated protein kinase 7, 4-[3,6-bis(chloranyl)-2-fluoranyl-phenyl]carbonyl-~{N}-(1-methylpyrazol-4-yl)-1~{H}-pyrrole-2-carboxamide (3 entities in total) |
| Functional Keywords | kinase, inhibitor, pyrrole, transferase |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 1 |
| Total formula weight | 41438.42 |
| Authors | Tucker, J.A.,Martin, M.P.,Endicott, J.A.,Noble, M.E.N. (deposition date: 2021-09-30, release date: 2022-05-11, Last modification date: 2024-01-31) |
| Primary citation | Miller, D.C.,Reuillon, T.,Molyneux, L.,Blackburn, T.,Cook, S.J.,Edwards, N.,Endicott, J.A.,Golding, B.T.,Griffin, R.J.,Hardcastle, I.,Harnor, S.J.,Heptinstall, A.,Lochhead, P.,Martin, M.P.,Martin, N.C.,Myers, S.,Newell, D.R.,Noble, R.A.,Phillips, N.,Rigoreau, L.,Thomas, H.,Tucker, J.A.,Wang, L.Z.,Waring, M.J.,Wong, A.C.,Wedge, S.R.,Noble, M.E.M.,Cano, C. Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. J.Med.Chem., 65:6513-6540, 2022 Cited by PubMed Abstract: The nonclassical extracellular signal-related kinase 5 (ERK5) mitogen-activated protein kinase pathway has been implicated in increased cellular proliferation, migration, survival, and angiogenesis; hence, ERK5 inhibition may be an attractive approach for cancer treatment. However, the development of selective ERK5 inhibitors has been challenging. Previously, we described the development of a pyrrole carboxamide high-throughput screening hit into a selective, submicromolar inhibitor of ERK5 kinase activity. Improvement in the ERK5 potency was necessary for the identification of a tool ERK5 inhibitor for target validation studies. Herein, we describe the optimization of this series to identify nanomolar pyrrole carboxamide inhibitors of ERK5 incorporating a basic center, which suffered from poor oral bioavailability. Parallel optimization of potency and pharmacokinetic parameters led to the identification of a nonbasic pyrazole analogue with an optimal balance of ERK5 inhibition and oral exposure. PubMed: 35468293DOI: 10.1021/acs.jmedchem.1c01756 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.59 Å) |
Structure validation
Download full validation report
